Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Olema Pharmaceuticals, Inc.

NASDAQ: OLMA · Life Sciences · 4 alerts · CIK 1750284

Share price
$7.36Close, Nov 16
Market cap
$645M
Shares outstanding
87.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Olema Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:11 AM ET 10-Q
Financial Results

Olema Pharmaceuticals Q3 2026 Results: Net Loss of $73.6M, Loss Widens

Olema Pharmaceuticals reported a net loss of $189.9 million for the first nine months of 2026, compared to $116.4 million in the prior year, driven by a significant increase in research and development expenses. The company maintained a strong liquidity position with $413.8 million in cash, cash equivalents, and marketable securities as of September 30, 2026.

Key figure
Net loss $73.6M
7:05 AM ET 8-K
Financial Results

Olema Pharmaceuticals Financial Results

Olema Pharmaceuticals reported a net loss of $73.6 million for the third quarter of 2026, driven by increased clinical trial enrollment costs. The company ended the period with $413.8 million in cash and remains on track to report pivotal Phase 3 OPERA-01 data in the first quarter of 2027.

Term
Q3 2026

“As we approach top-line data from our pivotal Phase 3 OPERA-01 trial in the first quarter of 2027, we remain confident in palazestrant’s potential to emerge as a differentiated endocrine therapy in second- and third-line metastatic breast cancer.”

Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer

“We believe that palazestrant, in combination with ribociclib, is well positioned to become the new standard of care in this setting. With its dual mechanism of action as a complete estrogen receptor antagonist and selective estrogen receptor degrader, optimal pharmacokinetic properties, encouraging clinical profile demonstrated to date, and potential for use both as a monotherapy and in combination with other agents, we believe palazestrant is uniquely positioned to transform the metastatic breast cancer treatment paradigm.”

Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.